A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS
Completed
Biogen
Phase 1
2009-02-28
To establish a pharmacokinetic (PK) profile of BG00012, as measured by its primary
metabolite, monomethyl fumarate (MMF), during a 24-hour dosing period in subjects with
relapsing-remitting multiple sclerosis (RRMS), with a variety of baseline demographic
characteristics.
The primary objective of this study is to evaluate the pharmacokinetics (PK) profile of
monomethyl fumarate (MMF) following delivery of BG00012 (dimethyl fumarate, DMF) 120 mg (Part
1) and BG00012 240 mg (Part 2) to varying regions within the GI tract in healthy volunteers.
The secondary objective of this study is to evaluate the safety and tolerability profile
following the delivery of BG00012 120 mg (Part 1) and BG00012 240 mg (Part 2) to varying
regions within the GI tract in healthy volunteers.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
